These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 18556456

  • 1. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
    Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, Li QQ, De Siervi A, Gardner K.
    Mol Pharmacol; 2008 Sep; 74(3):872-83. PubMed ID: 18556456
    [Abstract] [Full Text] [Related]

  • 2. Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
    Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A.
    Curr Pharm Biotechnol; 2015 Sep; 16(6):553-63. PubMed ID: 25860066
    [Abstract] [Full Text] [Related]

  • 3. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N, Dai Y, Rahmani M, Dent P, Grant S.
    Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
    [Abstract] [Full Text] [Related]

  • 4. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY, Dai Y, Grant S.
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [Abstract] [Full Text] [Related]

  • 5. Selective leukemic-cell killing by a novel functional class of thalidomide analogs.
    Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W, Ponciano-Jackson D, Chandramouli GV, Gardner ER, Figg WD, Abu-Asab M, Tsokos M, Jackson SH, Gardner K.
    Blood; 2006 Dec 15; 108(13):4126-35. PubMed ID: 16940421
    [Abstract] [Full Text] [Related]

  • 6. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.
    Leukemia; 2004 Nov 15; 18(11):1780-8. PubMed ID: 15385934
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y, Rahmani M, Grant S.
    Oncogene; 2003 Oct 16; 22(46):7108-22. PubMed ID: 14562039
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y, Rahmani M, Pei XY, Dent P, Grant S.
    Blood; 2004 Jul 15; 104(2):509-18. PubMed ID: 15039284
    [Abstract] [Full Text] [Related]

  • 9. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
    Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P.
    Mol Cancer Ther; 2007 Dec 15; 6(12 Pt 1):3101-12. PubMed ID: 18065490
    [Abstract] [Full Text] [Related]

  • 10. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.
    Cancer Res; 2012 Aug 15; 72(16):4225-37. PubMed ID: 22693249
    [Abstract] [Full Text] [Related]

  • 11. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.
    Mol Cancer Ther; 2007 Feb 15; 6(2):692-702. PubMed ID: 17308065
    [Abstract] [Full Text] [Related]

  • 12. 7b, a novel amonafide analog, inhibited proliferation and phorbol 12-myristate 13-acetate/phytohemagglutinin-induced inflammatory responses of Jurkat T cells via p73-dependent pathway and decrease of nuclear factor-κB DNA-binding, respectively.
    Shao J, Li Y, Shen K, Lin B, Xu Y, Lu Y, Yin P, Li Q, Liu J, Qian X.
    Leuk Lymphoma; 2013 Feb 15; 54(2):359-71. PubMed ID: 22762546
    [Abstract] [Full Text] [Related]

  • 13. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
    Dasmahapatra G, Almenara JA, Grant S.
    Mol Pharmacol; 2006 Jan 15; 69(1):288-98. PubMed ID: 16219908
    [Abstract] [Full Text] [Related]

  • 14. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S.
    Cancer Res; 2001 Mar 15; 61(6):2583-91. PubMed ID: 11289135
    [Abstract] [Full Text] [Related]

  • 15. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 15; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 16. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
    Takada Y, Sethi G, Sung B, Aggarwal BB.
    Mol Pharmacol; 2008 May 15; 73(5):1549-57. PubMed ID: 18287248
    [Abstract] [Full Text] [Related]

  • 17. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
    Alonso M, Tamasdan C, Miller DC, Newcomb EW.
    Mol Cancer Ther; 2003 Feb 15; 2(2):139-50. PubMed ID: 12589031
    [Abstract] [Full Text] [Related]

  • 18. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
    Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3502-9. PubMed ID: 16740776
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JH, Steiner F, Schrump DS.
    J Thorac Cardiovasc Surg; 2003 May 01; 125(5):1132-42. PubMed ID: 12771887
    [Abstract] [Full Text] [Related]

  • 20. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin.
    Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH.
    Med Oncol; 2010 Sep 01; 27(3):833-42. PubMed ID: 19763917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.